Niti U Trivedi
Overview
Explore the profile of Niti U Trivedi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trends in enforcement of National Comprehensive Cancer Network financial conflict of interest policy
Saririan N, Bhamidipati D, Dey P, Persaud S, Chakraborty N, Tabatabai S, et al.
JNCI Cancer Spectr
. 2024 Nov;
8(6).
PMID: 39589914
Background: The National Comprehensive Cancer Network (NCCN) financial conflict of interest (FCOI) policy sets dollar maximums for panelists, but violations may occur. Methods: We studied NCCN Guidelines panelists for the...
2.
Mitchell A, Persaud S, Mishra Meza A, Fuchs H, De P, Tabatabai S, et al.
J Clin Oncol
. 2024 Oct;
43(5):524-535.
PMID: 39393041
Purpose: The Medicare part D Low-Income Subsidy (LIS) improves access to oral cancer drugs, but provides no assistance for clinician-administered/part B drugs. This analysis assessed the association between LIS participation...
3.
Chakraborty N, Brown M, Persaud S, Gallagher G, Trivedi N, Bach P, et al.
JNCI Cancer Spectr
. 2024 Jun;
8(3).
PMID: 38825338
Background: Industry payments to US cancer centers are poorly understood. Methods: US National Cancer Institute (NCI)-designated comprehensive cancer centers were identified (n = 51). Industry payments to NCI-designated comprehensive cancer...
4.
Mitchell A, Dusetzina S, Mishra Meza A, Trivedi N, Bach P, Winn A
BMJ
. 2023 Oct;
383:e075512.
PMID: 37879723
Objective: To estimate the association between oncologists' receipt of payments from the pharmaceutical industry and delivery of non-recommended or low value interventions among their patients. Design: Cohort study. Setting: Fee-for-service...
5.
Trivedi N, Gargano L, Brackbill R, Jacobson M
J Trauma Stress
. 2022 Oct;
36(1):44-58.
PMID: 36239980
The September 11, 2001, terrorist attacks on the World Trade Center (WTC) in New York City (9/11) had health-related consequences, including posttraumatic stress disorder (PTSD). PTSD is associated with functional...
6.
Mitchell A, Mishra Meza A, Trivedi N, Bach P, Gonen M
Oncologist
. 2022 Aug;
27(10):857-863.
PMID: 35946837
Background: Drug manufacturers claim that the purpose of financial payments to physicians is to facilitate education about new drugs. This claim suggests 2 testable hypotheses: payments should not be associated...
7.
Mitchell A, Trivedi N, Bach P
Med Care
. 2022 Feb;
60(4):287-293.
PMID: 35149663
Background: The Prescription Drug User Fee Act (PDUFA) is due for reauthorization in 2022. Beyond creating the user fee program which now generates a majority of the Food and Drug...
8.
Rahman M, Trivedi N, Bach P, Mitchell A
J Natl Compr Canc Netw
. 2021 Dec;
20(13).
PMID: 34965511
Background: Personal payments from the pharmaceutical industry to US physicians are common and are associated with changes in physicians' clinical practice and interpretation of clinical trial results. We assessed temporal...
9.
Mitchell A, Mishra A, Dey P, Curry M, Trivedi N, Haddadin M, et al.
Oncologist
. 2021 Sep;
26(10):e1897.
PMID: 34546620
No abstract available.
10.
Mitchell A, Mishra A, Dey P, Curry M, Trivedi N, Haddadin M, et al.
Oncologist
. 2021 May;
26(9):771-778.
PMID: 33982829
Background: Oncologists who author clinical practice guidelines frequently have financial relationships with the pharmaceutical industry. It is unknown whether participation on clinical practice guideline committees is associated with differences in...